Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations (Q47703285)

4 February 2018

title

Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations (English)

1 reference

4 February 2018

1 reference

5

Jordan VC

1 reference

4 February 2018

author name string

Tonetti DA

1

1 reference

4 February 2018

O'Regan R

2

1 reference

4 February 2018

Tanjore S

3

1 reference

4 February 2018

England G

4

1 reference

4 February 2018

publication date

1 April 1998

1 reference

4 February 2018

The Journal of Steroid Biochemistry and Molecular Biology

published in

1 reference

4 February 2018

volume

65

1 reference

4 February 2018

issue

1-6

1 reference

4 February 2018

page(s)

181-189

1 reference

4 February 2018

The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Clinical potential of new antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Comparison between the Effects of Tamoxifen and Toremifene on the Uterus in Postmenopausal Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Protein kinase C--a question of specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Immunological quantitation of phospholipid/Ca2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Protein kinase C (PKC) isoenzyme expression pattern as an indicator of proliferative activity in uterine tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

Estrogen induces expression of c-fos and c-jun via activation of protein kinase C in an endometrial cancer cell line and fibroblasts derived from human uterine endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0960-0760%2898%2900011-9

7 January 2021

10.1016/S0960-0760(98)00011-9

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018